Gland Pharma (NSE:GLAND) Property, Plant and Equipment: ₹44,320 Mil (As of Mar. 2026)


NSE:GLAND Gland Pharma Ltd NSE:GLAND
83 GF Score
Price ₹2,462.30
GF Value ₹2,131.21
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Gland Pharma Property, Plant and Equipment?

Gland Pharma NSE:GLAND +0.66% 83 Property, Plant and Equipment is ₹44,320 Mil as of Mar. 2026. GuruFocus rates NSE:GLAND with a GF Score™ of 83/100 and a GF Value™ of ₹2,131.21 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Gland Pharma's quarterly net PPE declined from Sep. 2025 (₹42,183 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹44,320 Mil).

Gland Pharma's annual net PPE increased from Mar. 2024 (₹38,710 Mil) to Mar. 2025 (₹39,750 Mil) and increased from Mar. 2025 (₹39,750 Mil) to Mar. 2026 (₹44,320 Mil).


Gland Pharma  (NSE:GLAND) Property, Plant and Equipment Explanation

A company with durable competitive advantage doesn't need to constantly upgrade its equipment to stay competitive. The company replaces when it wears out. On the other hand, a company without any advantages must replace to keep pace.

Difference between a company with a moat and one without is that the company with the competitive advantage finances new equipment through internal cash flows, whereas the no advantage company requires debt to finance.

Producing a consistent product that doesn't change equates to consistent profits. There is no need to upgrade plants which frees up cash for other ventures. Think Coca Cola, Johnson & Johnson etc.


Gland Pharma Property, Plant and Equipment Related Terms


Gland Pharma Property, Plant and Equipment Historical Data

* Premium members only.

The historical data trend for Gland Pharma's Property, Plant and Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gland Pharma Property, Plant and Equipment Chart

Gland Pharma Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Property, Plant and Equipment
Get a 7-Day Free Trial Premium Member Only 17,268.97 17,990.64 38,710.02 39,749.90 44,320.21

Gland Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Property, Plant and Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39,749.90 0.00 42,182.88 0.00 44,320.21
NSE:GLAND
83GF Score
Gland Pharma Ltd NSE:GLAND
Property, Plant and Equipment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gland Pharma Property, Plant and Equipment Calculation

Property, Plant and Equipment (PPE) are the fixed assets of the companyFixed assets are also known as non-current assets.

Property, plant, and equipment includes assets that will - in the normal course of business - neither be used up in the next year nor will become a part of any product sold to customers.

Some of the most common parts of property, plant, and equipment are:


Land
Buildings (and leasehold improvements)
Transportation equipment
Manufacturing equipment
Office equipment
Office furniture

Companies with lots of property, plant, and equipment often have special categories. For example, railroad property includes:


Track
Ties
Ballast
Bridges
Tunnels
Signals
Locomotives
Freight Cars

There is often a note in the financial statements - found in a company's 10-K - that will explain the different categories of property a company owns.

The market value of property, plant, and equipment can differ tremendously from the book value of property, plant, and equipment.

For example, when Berkshire Hathaway liquidated its textile mills, it had to pay the buyers of the company's manufacturing equipment to haul the equipment away. That property, plant, and equipment was literally worth less than zero. On the other hand, some companies own thousands of acres of land.

All property, plant, and equipment other than land is depreciated. Land is never depreciated. However, land is not marked up to market value either. Under Generally Accepted Accounting Principles (GAAP), land is shown on the balance sheet at cost.

The property, plant, and equipment line shown on the balance sheet is usually net property, plant, and equipment. This means it is the cost of the property, plant, and equipment less accumulated depreciation.

What does a Property, Plant and Equipment of ₹44,320 Mil mean?
Gland Pharma (NSE:GLAND) has a Property, Plant and Equipment of ₹44,320 Mil as of Mar. 2026. The total property, plant and equipment recorded on a company's balance sheet less accumulated depreciation. View historical data on Gland Pharma and its competitors.
Is Gland Pharma's Property, Plant and Equipment too high?
Gland Pharma's current Property, Plant and Equipment is ₹44,320 Mil. Overall, Gland Pharma has a GF Score™ of 83/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gland Pharma's Property, Plant and Equipment compare to ZTS and UTHR?
Gland Pharma's Property, Plant and Equipment of ₹44,320 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Property, Plant and Equipment for a Drug Manufacturers company?
A good Property, Plant and Equipment depends on the Drug Manufacturers industry context. However, Property, Plant and Equipment should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Property, Plant and Equipment mean?
A high Property, Plant and Equipment can signal that a stock is expensive relative to its fundamentals. The total property, plant and equipment recorded on a company's balance sheet less accumulated depreciation. View historical data on Gland Pharma and its competitors. Gland Pharma's current Property, Plant and Equipment is ₹44,320 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gland Pharma stock overvalued right now?
Based on GuruFocus' analysis, Gland Pharma (NSE:GLAND) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,131.21, compared to a current price of ₹2,462.30 — trading 15.5% above its estimated fair value. The current Property, Plant and Equipment is ₹44,320 Mil. Gland Pharma's overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Property, Plant and Equipment calculated?
Property, Plant and Equipment is calculated from a company's financial statements. For Gland Pharma (NSE:GLAND), the current Property, Plant and Equipment is ₹44,320 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gland Pharma (NSE:GLAND) Overvalued in 2026?

Based on GuruFocus' analysis, Gland Pharma stock appears to be overvalued. The current stock price of ₹2,462.30 is trading 15.5% above its estimated GF Value™ of ₹2,131.21. GuruFocus considers Gland Pharma to be Modestly Overvalued.

Key valuation signals for NSE:GLAND:

  • Property, Plant and Equipment: ₹44,320 Mil
  • GF Value™: ₹2,131.21 vs. price of ₹2,462.30 (15.5% above fair value)
  • GF Score™: 83/100 with 6 warning signs

No single metric tells the full story. See the NSE:GLAND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Gland Pharma Business Description

Other Exchanges 543245:India
Address TSIIC, Phase - IV, Plot No. 11 and 84, Pashamylaram (V), Patancheru M, Sangareddy District, Hyderabad, TG, IND, 502307
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, and Daptomycin Injection, among others. The group is also involved in a vast range of therapeutic categories, including Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarials, Cardiology, and more, to Hormones and related Drugs, Fertility Supplements, and GnRH Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA, and the rest from Europe, India, Canada, Australia, and other regions.
83GF Score

Get the complete analysis for NSE:GLAND

Property, Plant and Equipment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,462.30
Price
₹2,131.21
GF Value